Janone begins production of jan101 cgmp batch for phase 2b pad trial & potential covid-19 study

Janone successfully begins production of jan101 cgmp batch for phase 2b peripheral artery disease (pad) trial and potential covid-19 study.janone inc - initial production batch will be 250,000 sustained release tablets and matching placebos.janone inc - phase 2b trials to treat peripheral artery disease is expected to begin in early 2021.
JAN Ratings Summary
JAN Quant Ranking